






Claims

1. A compound, wherein the compound is selected from A-3, A-4, A-20, A-37, A-55, and A-58, or an enantiomer of any of the foregoing, or a pharmaceutically acceptable salt of any of the foregoing:


A-3	
A-4	
A-20	
A-37	
A-55	
A-58	

2. The compound of claim 1, wherein the compound is: selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (A-3) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (A-60):




or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (A-4) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (A-61):




or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is selected from (*S*)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (A-20) and (*R*)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (A-64):




or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is selected from ((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-*L*-valinate (A-37) and ((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-*L*-valinate (A-67):




or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, wherein the compound is selected from 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (A-55) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate:



or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein the compound is selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (A-58) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (A-70):



or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is an oral formulation.

10. Use of the compound of any one of claims 1 to 7 or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 8 to 9 in the manufacture of a medicament for treating pain.

11. Use of the compound of any one of claims 1 to 7 or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 8 to 9 in the manufacture of a medicament for treating depression.

12. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 8 to 9 in the manufacture of a medicament for treating a neurological disorder or disease of the central nervous system related to NMDA receptor inhibition.

13. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 8 to 9 in the manufacture of a medicament for treating a psychiatric disorder or disease of the central nervous system related to NMDA receptor inhibition.